Boehringer Ingelheim has enrolled the first patient in RE-COVERY DVT/PE, a new study assessing the performance of its novel oral anticoagulant Pradaxa.
The global observational study will examine the management of deep vein thrombosis (DVT) and pulmonary embolism (PE) with Pradaxa in order to deliver insights into how patients are being treated in real-world clinical practice.
“Boehringer Ingelheim has launched a new study assessing the management of deep vein thrombosis and pulmonary embolism with Pradaxa.“
It will enroll up to 14,000 DVT/PE patients, who will receive treatment with Pradaxa or warfarin. Data on patient characteristics, including patient history and treatment patterns, will be collected alongside information on bleeding rates and recurrent symptomatic cases.
This will add to the growing body of data on the safety and effectiveness of Pradaxa compared to warfarin. The overall Boehringer Ingelheim research programme for Pradaxa involves more than 120,000 patients worldwide.
Dr Samuel Goldhaber, professor of medicine at Harvard Medical School, said: "We are launching RE-COVERY DVT/PE, an exciting new global prospective observational cohort study, to learn more about DVT and PE patient treatments and outcomes."See all the latest jobs in Pharmaceutical